A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

NACompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 1992

Conditions
Toxoplasmosis, CerebralHIV Infections
Interventions
DRUG

Pyrimethamine

Trial Locations (16)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

11201

Addiction Research and Treatment Corp, Brooklyn

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

23298

Richmond AIDS Consortium, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Comprehensive AIDS Alliance of Detroit, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

94110

Community Consortium of San Francisco, San Francisco

802044507

Denver CPCRA / Denver Public Hlth, Denver

972109951

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

06519

Hill Health Corp, New Haven

071032842

North Jersey Community Research Initiative, Newark

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000666 - A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection | Biotech Hunter | Biotech Hunter